title: Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
abstract: The purpose of this review is to provide an overview of the pharmacology, tolerability, and efficacy of the different phosphodiesterase type 5 (PDE5) inhibitors available for the treatment of erectile dysfunction (ED), with a special focus on the sildenafil orodispersible tablet (ODT) formulation.
  
  
  
  A literature search was performed in PubMed, EMBASE, and Cochrane Reviews using the terms erectile dysfunction, patient preference, sildenafil, and PDE5 inhibitors to identify articles published in English between May 1, 2006, and November 18, 2016. A total of 29 studies were included in this review.
  
  
  
  There are substantial data in the literature on the use of PDE5 inhibitors for the treatment of ED. Oral PDE5 inhibitors have been found to be efficacious in the treatment of ED based on results from standard tools used to assess treatment outcomes, such as the Global Assessment Questionnaire 1. In addition, PDE5 inhibitors are defined as well tolerated because of the low occurrence of serious adverse effects or discomfort. Mild adverse reactions, compared with a placebo, include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Both the film-coated tablet and ODT formulations of sildenafil with or without water have equivalent systemic exposure. However, use of a sildenafil ODT formulation offers a convenient alternative method of administration that would be advantageous for patients with ED.
  
  
  
  According to the published literature, the PDE5 inhibitors are considered an effective and well-tolerated option for the treatment of ED as determined by data generated from standard instruments used in the assessment of treatment outcomes in ED and reported types and severity of adverse effects. The sildenafil ODT formulation, which disintegrates rapidly in the mouth, is an alternative to the solid film-coated tablet formulation that offers administration benefit with the potential to improve treatment adherence, thereby enhancing the sexual health and sense of psychological well-being of patients and their partners.
authors.affiliation: Department of Oncology and Hemato-oncology, Pharmacology Unit, School of Medicine, University of Milan, Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Scaglione
authors.affiliation: Pfizer Ltd, Surrey, England.
authors.forename: Shaantanu
authors.initials: S
authors.lastname: Donde
authors.affiliation: Pfizer Inc, New York, New York, United States of America.
authors.forename: Tarek A
authors.initials: TA
authors.lastname: Hassan
authors.affiliation: Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Electronic address: eajannini@gmail.com.
authors.forename: Emmanuele A
authors.initials: EA
authors.lastname: Jannini
mesh_terms: D002626:Chemistry, Pharmaceutical; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068677:Sildenafil Citrate / Q000008:administration & dosage / Q000627:therapeutic use*; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D013607:Tablets; D000068677:Sildenafil Citrate
keywords: PDE5 inhibitor; erectile dysfunction; orodispersible tablet; sildenafil citrate